SCHEMBL3244920

SCHEMBL3244920

CC1CCCN1C(C)(C)C(NC(=O)c1c(Cl)cc(Cl)cc1Cl)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
SLC6A9 P48067 4/20 0.38
KCNK3 O14649 1/20 0.38
ITGB3 P05106 3/20 0.38
ITGA2B P08514 3/20 0.38
LMNA P02545 2/20 0.36
SPR P35270 3/20 0.36
KDM4E B2RXH2 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
DPP4 P27487 2/20 0.35
DPP8 Q6V1X1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3240061 0.85 KCNK3 (0.34) ALDH1A1SLC6A9KCNK3ITGB3ITGA2B
SCHEMBL3238566 0.85 SLC6A9 (0.40) ALDH1A1SLC6A9KCNK3ITGB3ITGA2B
SCHEMBL3232907 0.84 ALDH1A1 (0.39) ALDH1A1SLC6A9ITGB3ITGA2BLMNA
SCHEMBL3240097 0.84 SLC6A9 (0.46) ALDH1A1SLC6A9LMNAKDM4E
SCHEMBL3233196 0.84 SLC6A9 (0.42) ALDH1A1SLC6A9KCNK3KMT2A
SCHEMBL3241801 0.83 LMNA (0.40) ALDH1A1SLC6A9ITGB3ITGA2BLMNA
SCHEMBL3240092 0.82 SLC6A9 (0.47) ALDH1A1SLC6A9MEN1KMT2A
SCHEMBL3243834 0.81 P2RX7 (0.39) ALDH1A1KCNK3ITGB3ITGA2BCYP1A2
SCHEMBL3238447 0.80 SLC6A9 (0.40) ALDH1A1SLC6A9LMNAKDM4E
SCHEMBL3244796 0.80 TAS1R3 (0.44) ALDH1A1SLC6A9ITGB3ITGA2BLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
WO-2006067423-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287547-A1 Glycine Transport Inhibitors SLC18A2, SLC6A5, SLC1A2 ALDH1A1 1356/4885SLC6A9 13/4885KCNK3 1960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.